LRRK2-IN-22 

LRRK2-IN-22 is a LRRK2 inhibitor, with IC₅₀ values of 315.7 nM and 255.4 nM against LRRK2^WT and LRRK2^G2019S, respectively. LRRK2-IN-22 effectively inhibits LRRK2 kinase activity and downstream Rab10 phosphorylation, reduces ROS, and exhibits low cytotoxicity. LRRK2-IN-22 can be used for research on Parkinson's disease^[1].

LRRK2-IN-22 (Compound C-298) (0-10 μM; 24 h) exhibits low cytotoxicity in untransfected HEK293T cells, with an IC₅₀ of 3273 nM after 24 h of treatment^[1].
LRRK2-IN-22 (1-10 μM; 24 h) potently and dose-dependently inhibits ROS production, and its effect is stronger in HEK293T cells overexpressing LRRK2^G2019S than in cells overexpressing wild-type (WT) LRRK2^[1].
LRRK2-IN-22 (30-10000 nM; 4 h) potently and dose-dependently inhibits the phosphorylation of LRRK2 (Ser935) and Rab10 (Thr73), and exhibits higher potency against the LRRK2^G2019S mutant than wild-type LRRK2 in HEK293T cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

347.41

C₂₁H₂₁N₃O₂

1427947-55-4

COC1=CC=C(CC(N2CC=C(C3=CNC4=C3C=CC=N4)CC2)=O)C=C1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Gong X, et al. A Multistage Virtual Screening Strategy Integrating Molecular Similarity, Deep Learning Scoring, and Molecular Docking toward the Discovery of Novel LRRK2 Inhibitors. J Chem Inf Model. 2026;66(11):6706-6718.  [Content Brief]